Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2Gastrointestinal 2Head & Neck 1

Conditions

Opioid-Related Disorders 1Opioid-Induced Constipation 1Neoplasms 1Constipation 1

Interventions

Exercise 27Metformin 24Methods 14Radiotherapy 13Early Intervention, Educational 13Educational Status 12Counseling 12Surveys and Questionnaires 10Standard of Care 10Nutrition Assessment 9Resistance Training 8Diet Therapy 8Cisplatin 8naloxegol 7Tirzepatide 7Diet 7alvimopan 6Psychiatric Rehabilitation 6Fibroblast Growth Factor 7 6Caloric Restriction 6Radiation 5Low-Level Light Therapy 5Liraglutide 5Injections 5Exenatide 5Dexamethasone 5Cryotherapy 5semaglutide 4angiotensin I (1-7) 4Vitamin D 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × methylnaltrexone × Other × Clear all
NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

NCT01004393 2016-02-02

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

University of Vermont

Phase 2 Completed
12 enrolled 10 charts
Other

Constipation, Opioid-Related Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡